Verlyx Pharma

Verlyx Pharma Inc. is a privately-held pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. Verlyx’s lead product, VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. Verlyx has initiated a purposeful clinical program based on VLX103, aiming at three important unmet needs in the field of liver diseases: NASH and ASH. Verlyx Pharma relies on accomplished individuals whose complementary expertise brings a high level of knowledge, innovation and management to the company. This team coordinates a network of collaborators and investigators dedicated to the success of the company and its products.